Literature DB >> 21442237

Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro.

Shanrong Shu1, Yuebo Yang, Xiaomao Li, Tian Li, Yu Zhang, Chengfang Xu, Changyan Liang, Xiaoyun Wang.   

Abstract

The type-1 insulin-like growth factor receptor (IGF-1R) is over-expressed by endometrial carcinoma, level of IGF-1R has been correlated with tumor progression, and high IGF-1R expression has been found to be an important prognostic factor. In the study, we used lentivirus-mediated shRNA targeting IGF-1R to silence its expression, then assessed the effect of down-regulation of this receptor on cell growth and chemosensitivity to cisplatin. Lentivirus-mediate shRNA was designed and transfected to the endometrial carcinoma HEC-1B cell. The IGF-1R mRNA and related protein expression, cell proliferation ability, cell apoptosis, and cell cycle change were detected. Cell proliferation inhibition rates, cell apoptosis, and level of cleaved caspase-9 were measured in various concentrations of cisplatin. The mRNA and protein level of IGF-1R, and the phosphorylated protein p-Akt, p-Erk were all suppressed after transfection. Cell proliferation was inhibited in successive five days after transfection, the highest inhibition rate was 43.28 ± 3.55% on day 5. After transfection, 24.96 ± 1.05% cells were in G(2)/M phase, and cell apoptotic rate increased from 10.66 ± 0.08 to 19.92 ± 1.34%. In various concentrations of cisplatin, transfected cells proliferation was significantly inhibited which made the IC50 value drop from 21.85 uM to 10.58 uM. Incubation with different concentrations of cisplatin for 48 h, cells apoptotic rate increased to 41.92 ± 2.5, 31.13 ± 2.76, 22.21 ± 4.63%, respectively, which was accompanied with increased cleaved caspase-9 expression. Lentivirus-mediated shRNA targeting IGF-1R has the potential to develop as a clinical treatment method in advanced and chemoresistant endometrial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21442237     DOI: 10.1007/s11010-011-0790-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  RNA silencing as a natural antiviral defense system in mammals: where are we now?

Authors:  Sébastien Pfeffer
Journal:  Mol Ther       Date:  2010-05       Impact factor: 11.454

Review 2.  Systematic review of systemic therapy for advanced or recurrent endometrial cancer.

Authors:  Mark S Carey; Christine Gawlik; Michael Fung-Kee-Fung; Alexandra Chambers; Tom Oliver
Journal:  Gynecol Oncol       Date:  2006-01-24       Impact factor: 5.482

3.  Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway.

Authors:  S Kurihara; F Hakuno; S Takahashi
Journal:  Endocr J       Date:  2000-12       Impact factor: 2.349

4.  Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor.

Authors:  G O Hellawell; D J P Ferguson; S F Brewster; V M Macaulay
Journal:  BJU Int       Date:  2003-02       Impact factor: 5.588

5.  Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma.

Authors:  Shanrong Shu; Xiaomao Li; Yuebo Yang; Yu Zhang; Tian Li; Changyan Liang; Jing Wan
Journal:  Int Immunopharmacol       Date:  2010-12-09       Impact factor: 4.932

6.  Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro.

Authors:  Kamal Yavari; Mohammad Taghikhani; Mohammad Ghannadi Maragheh; Seyed A Mesbah-Namin; Mohammad Hosein Babaei
Journal:  Arch Med Res       Date:  2009-05       Impact factor: 2.235

Review 7.  The insulin-like growth factor-I receptor as an oncogene.

Authors:  Haim Werner; Ilan Bruchim
Journal:  Arch Physiol Biochem       Date:  2009-05       Impact factor: 4.076

Review 8.  Insulin, insulin-like growth factors and neoplasia.

Authors:  Michael Pollak
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-08       Impact factor: 4.690

9.  Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.

Authors:  Junya Furukawa; Christopher J Wraight; Susan M Freier; Eigan Peralta; Lynne M Atley; Brett P Monia; Martin E Gleave; Michael E Cox
Journal:  Prostate       Date:  2010-02-01       Impact factor: 4.104

10.  A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells.

Authors:  Deepali Sachdev; Julie S Hartell; Adrian V Lee; Xihong Zhang; Douglas Yee
Journal:  J Biol Chem       Date:  2003-11-13       Impact factor: 5.157

View more
  7 in total

1.  Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.

Authors:  Erica Gentilin; Mariella Minoia; Marta Bondanelli; Federico Tagliati; Ettore C Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2016-09-01       Impact factor: 3.633

2.  MiR-223 suppresses endometrial carcinoma cells proliferation by targeting IGF-1R.

Authors:  Kai Huang; Xiyuan Dong; Cong Sui; Dan Hu; Ting Xiong; Shujie Liao; Hanwang Zhang
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

3.  Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.

Authors:  Mark J Jameson; Andrew D Beckler; Linnea E Taniguchi; Amir Allak; Lisa B Vanwagner; Nora G Lee; William C Thomsen; Matthew A Hubbard; Christopher Y Thomas
Journal:  Mol Cancer Ther       Date:  2011-08-30       Impact factor: 6.261

4.  Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.

Authors:  Xiaodong Tian; Kun Hao; Changfu Qin; Kun Xie; Xuehai Xie; Yinmo Yang
Journal:  Dig Dis Sci       Date:  2013-04-16       Impact factor: 3.199

5.  Higher Expression of Proteins in IGF/IR Axes in Colorectal Cancer is Associated with Type 2 Diabetes Mellitus.

Authors:  Jing Ding; Cong Li; Jie Tang; Cheng Yi; Ji-Yan Liu; Meng Qiu
Journal:  Pathol Oncol Res       Date:  2016-05-02       Impact factor: 3.201

Review 6.  Ion Channels in Endometrial Cancer.

Authors:  Bruna Pasqualotto Costa; Fernanda Bordignon Nunes; Francini Corrêa Noal; Gisele Branchini
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

7.  DDAB cationic lipid-mPEG, PCL copolymer hybrid nano-carrier synthesis and application for delivery of siRNA targeting IGF-1R into breast cancer cells.

Authors:  M Khodaei; K Rostamizadeh; A H Taromchi; H Monirinasab; M Fathi
Journal:  Clin Transl Oncol       Date:  2021-01-03       Impact factor: 3.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.